{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tan CS"],"funding":["NICHD NIH HHS","NIAID NIH HHS","NIGMS NIH HHS"],"pagination":["e2226335"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9366542"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(8)"],"pubmed_abstract":["<h4>Importance</h4>Antibody responses elicited by current messenger RNA (mRNA) COVID-19 vaccines decline rapidly and require repeated boosting.<h4>Objective</h4>To evaluate the immunogenicity and durability of heterologous and homologous prime-boost regimens involving the adenovirus vector vaccine Ad26.COV2.S and the mRNA vaccine BNT162b2.<h4>Design, setting, and participants</h4>In this cohort study at a single clinical site in Boston, Massachusetts, 68 individuals who were vaccinated at least 6 months previously with 2 immunizations of BNT162b2 were boosted with either Ad26.COV2.S or BNT162b2. Enrollment of participants occurred from August 12, 2021, to October 25, 2021, and this study involved 4 months of follow-up. Data analysis was performed from November 2021 to February 2022.<h4>Exp"],"journal":["JAMA network open"],"pubmed_title":["Durability of Heterologous and Homologous COVID-19 Vaccine Boosts."],"pmcid":["PMC9366542"],"funding_grant_id":["T32 GM144273","T32 GM007753","K12 HD000849","T32 GM008313","F30 AI160908","R21 AI169309"],"pubmed_authors":["McMahan K","Liu J","Roy V","Schmidt AG","Yu J","Hauser BM","Sadoff J","Tan CS","Alter G","Jacob-Dolan C","Meganck RM","Rowe M","Jaegle KH","Hemond R","Barouch DH","Munt JE","Powers JM","Le Gars M","Mallory ML","Mattocks M","Baric RS","He X","Bondzie EA","Collier AY","Chandrashekar A"],"additional_accession":[]},"is_claimable":false,"name":"Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.","description":"<h4>Importance</h4>Antibody responses elicited by current messenger RNA (mRNA) COVID-19 vaccines decline rapidly and require repeated boosting.<h4>Objective</h4>To evaluate the immunogenicity and durability of heterologous and homologous prime-boost regimens involving the adenovirus vector vaccine Ad26.COV2.S and the mRNA vaccine BNT162b2.<h4>Design, setting, and participants</h4>In this cohort study at a single clinical site in Boston, Massachusetts, 68 individuals who were vaccinated at least 6 months previously with 2 immunizations of BNT162b2 were boosted with either Ad26.COV2.S or BNT162b2. Enrollment of participants occurred from August 12, 2021, to October 25, 2021, and this study involved 4 months of follow-up. Data analysis was performed from November 2021 to February 2022.<h4>Exp","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-06-01T02:21:09.018Z","creation":"2025-04-19T05:56:37.109Z"},"accession":"S-EPMC9366542","cross_references":{"pubmed":["35947380"],"doi":["10.1001/jamanetworkopen.2022.26335"]}}